• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Anika launches late-stage supplemental Cingal study

May 26, 2017 By Sarah Faulkner

Anika TherapeuticsAnika Therapeutics (NSDQ:ANIK) said yesterday that it enrolled the 1st patient in a supplemental Phase III efficacy and safety trial of its Cingal hyaluronic acid-corticosteroid combination viscosupplement.

The Bedford, Mass.-bsaed company is evaluating Cingal as a treatment for osteoarthritis-related knee pain.

The supplemental late-stage trial is slated to enroll patients at 30 European sites and randomize them to receive Cingal, Monovisc or triamcinolone hexacetonide. Researchers will follow the patients for 26 weeks and monitor safety as well as changes in pain, function and quality of life measures.

“Advancing Cingal towards FDA approval is 1 of our key business priorities, and the enrollment of the 1st patient in our supplemental Phase III trial is an important step towards achieving that goal,” president & CEO Charles Sherwood said in prepared remarks.

The company said it expects to finish the trial in 2018 and to win FDA approval the following year.

Cingal was the 1st viscosupplement to combine triamcinolone hexacetonide, an FDA-approved steroid, with Anika’s cross-linked hyaluronic acid, according to the company. Healthcare professionals inject viscosupplements into synovial joints to rejuvenate the natural cushioning that degrades with age and degenerative orthopedic diseases.

Earlier this week, Anika touted data from the Phase III trial that supported Cingal’s Health Canada and CE mark approvals.

The data showed that treatment with Cingal yielded better immediate and short-term pain relief compared to hyaluronic acid alone and better pain and stiffness relief through 26 weeks compared to saline.

ANIK shares were trading at $46.77 apiece in morning activity today, up 0.7%.

Filed Under: Clinical Trials, Featured, Orthopedics, Pharmaceuticals, Regenerative Medicine, Wall Street Beat Tagged With: Anika Therapeutics Inc.

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS